MedPath

Vision II: Evaluation of GALILEO Intravascular Radiotherapy System

Phase 4
Completed
Conditions
Coronary Artery Disease
Interventions
Device: Guidant GALILEO Intravascular Radiotherapy System
Registration Number
NCT00180583
Lead Sponsor
Abbott Medical Devices
Brief Summary

To assess the safety and effectiveness of intravascular brachytherapy for the treatment of intrastent restenosis of coronary lesions with the Galileo system

Detailed Description

The purpose of this study is to evaluate the cardiac events (MACE) and adverse extra cardiac events at 6 month follow up and up to 24 months for the patients treated with Galileo system

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
268
Inclusion Criteria
  • Patient with angor, patients with only one de novo lesion. Target zone must be < 52 mm, artery section must be < 3,7mm and > 2,25 mm
Exclusion Criteria
  • Vessel with extremely tortuous proximal segment, lesion with angulous segments (>90°) Unstable ventricular arrhythmia, dialysis, MI within the last 72 hours etc...

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
1Guidant GALILEO Intravascular Radiotherapy SystemTreatment of single or multivessel long diffuse coronary stenosis with the Guidant GALILEO Intravascular Radiotherapy System
Primary Outcome Measures
NameTimeMethod
MACE6 months
Secondary Outcome Measures
NameTimeMethod
All adverse cardiac or extra cardiac events24-month

Trial Locations

Locations (1)

Clinique St. Hilaire

🇫🇷

Rouen, France

© Copyright 2025. All Rights Reserved by MedPath